Cargando…

ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study

INTRODUCTION: Tolerability and convenience are crucial aspects for the long-term success of combined antiretroviral therapy (cART). The aim of this study was to investigate the impact in routine clinical practice of switching to the single tablet regimen (STR) RPV/FTC/TDF in patients with intoleranc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Podzamczer, Daniel, Rozas, Nerea, Domingo, Pere, Ocampo, Antonio, Van den Eynde, Eva, Deig, Elisabeth, Vergara, Antonio, Knobel, Hernando, Pasquau, Juan, Antela, Antonio, Crespo, Manuel, Clotet, Bonaventure, Muñoz, Jessica, Fernandez, Pedro, Geijo, Paloma, Rodríguez de Castro, Eduardo, Diz, Julio, Casado, Araceli, Torres, Covadonga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P282
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225323/ https://www.ncbi.nlm.nih.gov/pubmed/25397558 http://dx.doi.org/10.7448/IAS.17.4.19814

Ejemplares similares

Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA(®), Because of a Previous Intolerance to cART. PRO-STR Study
por: Podzamczer, D., et al.
Publicado: (2018)

Oxygénothérapie de haut débit dans la prise en charge précoce des patients atteints de pneumopathie à Covid-19
por: Schilfarth, P., et al.
Publicado: (2022)

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials
por: Hagins, D, et al.
Publicado: (2018)

Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV
por: Munderi, Paula, et al.
Publicado: (2019)

Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial
por: Curran, Adrian, et al.
Publicado: (2020)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

538 A Retrospective Study to Evaluate the Safety of Switching Antiretroviral Therapy (ART) to Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) STR in Virologically Suppressed HIV-Infected Patients
por: Monczor, Ana, et al.
Publicado: (2014)

Lipid changes in HIV-patients switching to the coformulated single tablet FTC/RPV/TDF (Eviplera(®)). Efficacy and safety analysis. GeSida Study 8114
por: Pérez-Hernández, Isabel A, et al.
Publicado: (2014)

Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
por: Wiriyatanakorn, Sirichai, et al.
Publicado: (2019)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
por: Stellbrink, Hans-Juergen, et al.
Publicado: (2014)

Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC
por: Ramón Santos, José, et al.
Publicado: (2014)

Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naïve subjects ≥50 years
por: Gazzard, Brian, et al.
Publicado: (2014)

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study
por: Martínez, E, et al.
Publicado: (2010)

Naïve patients receiving TDF/FTC-EFV as 2 pills are more likely to modify regimen components than patients receiving a TDF/FTC/EFV single pill
por: Perez-Valero, I, et al.
Publicado: (2010)

Switching from an EFV-based STR to a RPV-based STR is effective, safe and improves HIV patients health status
por: Maggiolo, Franco, et al.
Publicado: (2014)

Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study
por: Giacomelli, Andrea, et al.
Publicado: (2021)

Adherence to daily, oral TDF/FTC PrEP during periconception among HIV-exposed South African women
por: Hurwitz, Kathleen E., et al.
Publicado: (2023)

5-year safety and efficacy of the once-daily antiretroviral regimen of efavirenz (EFV)/emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
por: Lazzarin, A, et al.
Publicado: (2010)

1298. Acquisition of TDF-Susceptible HIV Despite High Level Adherence to Daily TDF/FTC PrEP as Measured by Dried Blood Spot (DBS) and Segmental Hair Analysis: A Case Report
por: Cohen, Stephanie E, et al.
Publicado: (2018)

1587. SOLAR 12-Month North American Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF
por: McKellar, Mehri, et al.
Publicado: (2023)

EFICÁCIA E TOXICIDADE DE TENOFOVIR (TDF) E ENTRICITABINA (FTC) PARA INFECÇÕES LEVE A MODERADA PELO SARS-COV-2
por: de Arruda, Erico Antonio Gomes, et al.
Publicado: (2022)

Efficacy and safety of TDF/FTC-containing, first-line HAART in clinical practice: 3-year data from the German outpatient cohort
por: van Lunzen, J, et al.
Publicado: (2010)

Efficacy and safety of TDF+FTC+EFV in naïve patients initiating HAART; an observational study comparing Atripla Vs Truvada/Sustiva exposure
por: Sanchez, Carlos Alberto, et al.
Publicado: (2010)

Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
por: Peng, Siyang, et al.
Publicado: (2014)

Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
por: Billaud, E, et al.
Publicado: (2010)

Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis
por: Arribas, Jose, et al.
Publicado: (2014)

1024. Impact of Treatment Adherence on Efficacy of DTG/3TC and DTG + TDF/FTC: Pooled Analysis of the GEMINI 1 and 2 Clinical Trials
por: Ait-Khaled, Mounir, et al.
Publicado: (2020)

HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)
por: Baran, RW, et al.
Publicado: (2010)

How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP
por: Pilkington, Victoria, et al.
Publicado: (2018)

Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW)
por: Defechereux, Patricia A., et al.
Publicado: (2015)

Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data
por: DeJesus, E, et al.
Publicado: (2010)

Rpv29, Rpv30 and Rpv31: Three Novel Genomic Loci Associated With Resistance to Plasmopara viticola in Vitis vinifera
por: Sargolzaei, Maryam, et al.
Publicado: (2020)

SUSY RPV Searches
por: Zhuang, Xuai
Publicado: (2017)

RPV Models Overview
por: Nangia, Saurabh
Publicado: (2022)

Switching to Atripla (EFV/FTC/TDF) from Kivexa (ABC/3TC) plus EFV leads to improved perceptions of treatment: results from the ROCKET 1 study
por: Cooper, V, et al.
Publicado: (2010)

Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients
por: Gatell, Josep M, et al.
Publicado: (2014)

Grapevine Rpv3-, Rpv10- and Rpv12-mediated defense responses against Plasmopara viticola and the impact of their deployment on fungicide use in viticulture
por: Wingerter, Chantal, et al.
Publicado: (2021)

319. SWORD 1 and 2: Switch from TDF Containing Regimen to DTG+RPV Maintains Bone Mineral Density and Decreases Bone Turnover Markers Over 148 Weeks
por: Kahl, Lesley, et al.
Publicado: (2019)

48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
por: Yazdanpanah, Y, et al.
Publicado: (2014)

Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era
por: Sterrantino, Gaetana, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8mot5g28m21bqajtfccea5mcqn